Source comparison
Mechanism of Action — Central vs Peripheral Pathways
PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus and limbic system. Brain regions responsible for sexual motivation and reward processing. When bound, these receptors trigger dopaminergic and noradrenergic signaling cascades that enhan
This comparison does not assign a generated winner or score.
- PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus and limbic system. Brain regions responsible for sexual motivation and reward processing. When bound, these receptors trigger dopaminergic and noradrenergic signaling cascades that enhance arousal, desire, and genital sensitivity independent of tactile stimulation. The effect is centrally mediated. It doesn't require existing erectile capacity or normal vascular function. Studies in hypogonadal men with suppressed libido showed significant increases in spontaneous erections and desire ratings within 60–90 minutes of subcutaneous administration, even when baseline testosterone remained low. PT-141's mechanism bypasses peripheral vasculature entirely.
- Cialis inhibits PDE5, the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in smooth muscle cells lining blood vessels in the corpus cavernosum. During sexual arousal, nitric oxide release from endothelial cells activates guanylate cyclase, which synthesizes cGMP. The molecule responsible for smooth muscle relaxation and increased blood flow. PDE5 normally degrades cGMP within minutes, ending the erection. By blocking PDE5, Cialis extends cGMP half-life from 5 minutes to 17.5 hours, allowing prolonged vasodilation in response to natural arousal signals. The medication doesn't initiate arousal. It amplifies the vascular response to existing sexual stimuli.
- The PT-141 vs Cialis distinction comes down to initiation versus amplification. PT-141 creates the desire signal where it's absent or suppressed; Cialis enhances the physical capacity to respond to desire signals that already exist. This is why combination protocols sometimes appear in research settings. Patients with both central arousal deficits and vascular impairment may benefit from dual-pathway intervention. Our experience shows that most users misidentify the impaired system: low desire blamed on vascular issues, or vascular insufficiency attributed to psychological factors. Mechanism clarity prevents months of ineffective treatment.